Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.57 |
| ▸ | MMP13 | P45452 | 14/20 | 0.57 |
| ▸ | MMP1 | P03956 | 9/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769210 | 0.86 | MMP2 (0.52) | MMP2MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL6769491 | 0.85 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL6767568 | 0.85 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL6767563 | 0.85 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL6766794 | 0.76 | MMP2 (0.49) | MMP2MMP13MMP1ALDH1A1 | |
| SCHEMBL7299694 | 0.73 | MMP13 (0.62) | MMP2MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL6769208 | 0.72 | ALDH1A1 (0.52) | ALDH1A1POLB | |
| SCHEMBL15085812 | 0.70 | HTT (0.60) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6767619 | 0.69 | CYP2C19 (0.55) | MMP2MMP13MMP1ALDH1A1 | |
| SCHEMBL6764638 | 0.69 | MMP13 (0.67) | MMP2MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716844-B2 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| EP-0984959-B1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173508-A1 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | PHARMACIA CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-6362183-B1 | PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS | G. D. SEARLE & COMPANY | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173508-A1 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | MMP1, MMP2, MMP3 | MMP2 2/4885MMP13 9/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.